Association for Research in Vision and Ophthalmology
Association for Research in Vision and Ophthalmology
May 01, 2018
1 min watch
Save

VIDEO: ROCKET 2 demonstrates comparable efficacy of Rhopressa, timolol

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

HONOLULU — The ROCKET 2 trial found once-daily treatment with Aerie Pharmaceuticals’ Rhopressa (netarsudil ophthalmic solution 0.02%) to be comparable with twice-daily treatment with timolol maleate 0.05% while maintaining a similar side effect profile, Janet B. Serle, MD, said at the Association for Research in Vision and Ophthalmology meeting here.